Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured

Krystal Biotech, Inc.

2025-Q1 EPS reported $1.20 revenue$88,183,000

VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.
Net income $35.7M ($1.24 basic EPS) vs $0.9M ($0.03) year ago; cash $765.3M.
European Commission approved VYJUVEK for DEB; first Germany launch mid-2025; Japan decision expected 2H2025.
Second ophthalmic program KB801 IND cleared for neurotrophic keratitis; Phase 1/2 EMERALD-1 starts May 2025.
FY2025 non-GAAP R&D+SG&A guidance $150-175M; upcoming readouts for CF, AATD, ocular DEB, aesthetics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.